FMI opines the GLP-1 obesity implant market was valued at USD 59.1 million in 2025. The industry is expected to reach USD 76.0 million in 2026 and USD 932.9 million by 2036. Exenatide implants are poised to dominate by molecule type with 54.0% share in 2026, and 6-month implants are expected to lead by duration profile through the forecast period.